natgillin/translations-raw huggingface dataset:
Spontaneous reports have been very rarely received on tremor, hypertonia, lethargy and sleepiness, in infants born to mothers who had used olanzapine during the 3rd trimester.
Zelo redko so poroč o tresenju, hipertoniji, letargiji in zaspanosti pri dojenč rojenih materam, ki
In a study in lactating, healthy women, olanzapine was excreted in breast milk.
V raziskavi na zdravih doječ ž ih enskah so ugotovili, da se olanzapin izloč v materino a mleko.
Mean infant exposure (mg/ kg) at steady state was estimated to be 1.8% of the maternal olanzapine dose (mg/ kg).
Ocenili so, da dojenč od matere, ki je dolgotrajno jemala olanzapin, dobi 1, 8% materinega ek odmerka olanzapina (mg/ kg).
No studies on the effects on the ability to drive and use machines have been performed.
Raziskave o vplivu na sposobnost za vož in upravljanje strojev niso bile narejene.
Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.
nost, zato je treba bolnike opozoriti, naj bodo previdni pri vož nji
Adults The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic transaminases (see section 4.4), rash, asthenia, fatigue and oedema.
poveč telesne mase, eozinofilija, zviš vrednosti prolaktina, holesterola, glukoze in trigliceridov
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
(gl. poglavje 4. 4), glikozurija, poveč apetit, omotica, akatizija, parkinsonizem (gl. poglavje 4. 4), an diskinezija, ortostatska hipotenzija, antiholinergič uč ni inki, prehodna asimptomatska zviš ravnianja č jetrnih transaminaz (gl. poglavje 4. 4), izpušaj, astenija, utrujenost in edem.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
V tabeli 1 so navedeni než eleni učinki, ki so jih navajali bolniki, in laboratorijske preiskave, ki so jih izvajali med kliničnimi preizkuš Než
The frequency terms listed are defined as follows:
so navedeni po padajočresnosti, njihova inki i
10%), common (≥ 1% and < 10%), uncommon (≥ 0.1% and < 1%), rare (≥ 0.01% and
pogostost pa je definirana z naslednjimi opisi: zelo pogosti (≥10%), pogosti (≥1% in < 10%), obč (≥0, 1% in < 1%), redki (≥0, 01% in < 0, 1%), zelo redki (< 0, 01%), ni znano (ocena iz asni danih podatkov ni mož
< 0.1%), very rare (< 0.01%), not known (cannot be estimated from the data available).
Pogostost neželenih učinkov in laboratorijske preiskave Zelo pogosti
Common
Obč asni
Uncommon
Ni znano
Not known
Bolezni krvi in limfatičnega sistema
Blood and the lymphatic system disorders Immune system disorders
Bolezni imunskega sistema alergijska reakcija Presnovne in prehranske motnje poveč telesne
Eosinophilia
vrednosti ane
Leukopenia Neutropenia
razvoj ali poslabš anje
Thrombocytopenia Allergic reaction
holesterola 2, 3 zviš vrednosti
Metabolism and nutrition
sladkorne bolezni,
disorders
vključ z nekaj no
Weight gain1
trigliceridov 2, 5 glikozurija poveč apetit
Elevated cholesterol levels 2,3 Elevated glucose levels 4 Elevated triglyceride levels 2,5 Glucosuria Increased appetite
smrtnimi primeri (gl. poglavje 4. 4)
Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4) Hypothermia
an
Nervous system disorders Somnolence
hipotermija
Dizziness Akathisia6
7 zaspanost
Seizures where in most cases a history of
epileptič napadi, ki ni
7
jih je več bolnikov ina ž imela ali pa je o njih
Cardiac disorders
Srč bolezni ne
Parkinsonism6 Dyskinesia 6
parkinsonizem6 diskinezije6
seizures or risk factors for seizures were reported Neuroleptic malignant syndrome (see section 4.4) Dystonia (including oculogyration) Tardive dyskinesia Discontinuation symptoms7
e poroč ala nevroleptič maligni ni sindrom (gl. poglavje 4. 4) distonija (vključ z no okulogiracijo) tardivne diskinezije odtegnitveni simptomi7
Bradycardia QT c prolongation (see section 4.4)
anje QTc (gl. poglavje 4. 4)
Ventricular tachycardia/ fibrillation, sudden death (see section 4.4)
tahikardija/ fibrilacijane nadna smrt (gl. poglavje 4. 4)
Thromboembolism (including pulmonary embolism and deep vein thrombosis)
trombembolija (vključ s pljuč no no embolijo in globoko vensko trombozo)
Gastrointestinal disorders
pankreatitis
Mild, transient anticholinergic effects including constipation and dry mouth
Bolezni jeter, ž nika in ž evodov
Pancreatitis
hepatocelularno,
Hepato-biliary disorders
Bolezni kož in podkož
Transient, asymptomatic elevations of hepatic transaminases (ALT, AST), especially in early treatment (see section 4.4)
anja transaminaz (ALT, AST), posebno na zač zdravljenja (gl. etku poglavje 4. 4)
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)
holestatsko ali meš ano jetrno okvaro)
Skin and subcutaneous tissue disorders
fotosenzitivnostne reakcije alopecija
Rash
etkom
Photosensitivity reaction Alopecia
zviš raven alkalne ana
Musculoskeletal and connective tissue disorders Rhabdomyolysis Renal and urinary disorders Urinary hesitation Reproductive system and breast disorders Priapism General disorders and administration site conditions Asthenia Fatigue Oedema Investigations Elevated plasma prolactin levels 8 1
koncentracije prolaktina 8
High creatine phosphokinase Increased total bilirubin
fosfokinaze poveč skupni an bilirubin
Increased alkaine phosphatase
fosfataze
Clinically significant weight gain was observed
8 č 1 Klinič pomembno poveč telesne mase so opazili pri vseh izhodišnih indeksih telesne mase
across all baseline Body Mass
anje
Index (BMI)
(ITM).
categories.
≥15% pa je bilo pogosto.
Weight gain ≥ 7% of baseline body weight was very common and ≥
Poveč izhodišne telesne mase za ≥25% je bilo pri dolgotrajnem č anje jemanju olanzapina zelo pogosto.
15% of baseline body
č 2 Povpreč poveč vrednosti lipidov na teše (skupni holesterol, holesterol LDL in trigliceridi) je
8
no
weight was common.
č
Patients gaining ≥ 25% of their baseline body weight with long-term exposure were very common.
bilo več pri bolnikih, pri katerih v izhodišu ni bila dokazana motnja v delovanju lipidov. je
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
č 3 Opazovano pri normalnih osnovnih vrednostih na teše (< 5, 17 mmol/ l), ki so se zviš na visoke ale č (≥6, 2 mmol/ l).
4 Observed for fasting normal levels at baseline (< 5.56 mmol/ l) which increased to high (≥ 7 mmol/ l).
6, 2
Changes in fasting glucose from borderline at baseline (≥ 5.56 - < 7 mmol/ l) to high (≥ 7 mmol/ l) were very common.
č 4 Opazovano pri normalnih osnovnih vrednostih na teše (< 5, 56 mmol/ l), ki so se zviš na visoke ale č (≥7 mmol/ l).
5 Observed for fasting normal levels at baseline (< 1.69 mmol/ l) which increased to high (≥ 2.26 mmol/ l).
7
Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/ l - < 2.26 mmol/ l) to high (≥ 2.26 mmol/ l) were very common.
Spremembe vrednosti trigliceridov na teše z mejnih izhodišnih vrednosti (od ≥1, 69 do < 2, 26 mmol/ l) na visoke (≥2, 26 mmol/ l) so bile zelo 6 V klinič preizkuš
6 In clinical trials, the incidence of parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo.
anjih je bila incidenca parkinsonizma in distonije pri bolnikih, zdravljenih z
Olanzapine-treated patients had a lower incidence of parkinsonism, akathisia and dystonia compared with titrated doses of haloperidol.
Pri
In the absence of detailed information on the pre-existing history of individual acute and tardive extrapyramidal movement disorders, it can not be concluded at present that olanzapine produces less tardive dyskinesia and/ or other tardive extrapyramidal syndromes.
Zaradi pomanjkanja podrobnih anamnestič podatkov o preteklih posameznih akutnih in poznih ekstrapiramidnih nih motnjah gibanja trenutno ni mož sklepati, da povzroč olanzapin manj tardivnih diskinezij in/ ali drugih zapoznelih ekstrapiramidnih 7
7 Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly.
Pri nenadni prekinitvi zdravljenja z olanzapinom so poroč o akutnih simptomih, kot so znojenje, ali nespeč nost, tresenje, tesnoba, slabost in bruhanje.
8 Associated clinical manifestations (e. g., gynaecomastia, galactorrhoea, and breast enlargement) were rare.
Pri
In most patients, levels returned to normal ranges without cessation of treatment.
več bolnikov so se ravni vrnile na normalne ne da bi bilo treba ukiniti zdravljenje. ini
Long-term exposure (at least 48 weeks) The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/ LDL/ HDL cholesterol or triglycerides increased over time.
Dolgotrajna izpostavljenost (najmanj 48 tednov) Delež bolnikov s klinič znač
In adult patients who completed 9-12 months of therapy, the rate of increase in mean blood glucose slowed after approximately 4-6 months.
ilnimi spremembami telesne mase, glukoze, skupnega holesterola ter
Additional information on special populations In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see also section 4.4).
holesterolov LDL in HDL ali trigliceridov se je sč asoma poveč Pri odraslih bolnikih, ki so konč 9 - do 12- meseč zdravljenje, se je poveč
Very common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and falls.
Pogosto so opaž pljuč
Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.
temperaturo, letargijo, eritem, vidne halucinacije ter inkontinenco urina.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’ s disease, worsening of Parkinsonian symptomatology and ha llucinations were reported very commonly and more frequently than with placebo.
povezana s Parkinsonovo boleznijo, so pogosto ter pogosteje kot pri placebu poroč o poslabš simptomatike Parkinsonove bolezni in halucinacijah.
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels.
valproatom in olanzapinom povzroč nevtropenije pri 4, 1% bolnikov; mož vzroč dejavnik so
Olanzapine administered with lithium or valproate resulted in increased levels ( 10%) of tremor, dry mouth, increased appetite, and weight gain.
Pogosto
Speech disorder was also reported commonly.
so poroč tudi o motnji govora.
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Med zdravljenjem z olanzapinom v kombinaciji z litijem ali ali divalproeksom se je 17, 4% bolnikov med akutnim zdravljenjem (do 6 tednov) poveč telesna masa, ala
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of  from baseline body weight in 39.9% of 7% patients.
Dolgotrajno zdravljenje z olanzapinom (do 12 mesecev) za prepreč evanje ponovnega pojava bolezni pri bolnikih z bipolarno motnjo je bilo povezano s anjem telesne mase za ≥% z osnovne pri 39, 9% bolnikov. poveč 7
9 Children and adolescents Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years.
Posebnih klinič
Although no clinical studies designed to compare adolescents to adults have been conducted, data from the adolescent trials were compared to those of the adult trials.
raziskav, v katerih bi primerjali mladostnike in odrasle, niso izvedli, so pa podatke iz preizkuš na anj mladostnikih primerjali s podatki iz preizkuš na odraslih. anj
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients.
17 let) kot pri odraslih bolnikih, in než elene uč inke, ki so jih ugotovili samo v kratkotrajnih klinič nih preizkuš anjih na mladostnikih.
Clinically significant weight gain (≥ 7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures.
Iz podatkov je razvidno, da je klinič pomembno poveč telesne
The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.
Obseg poveč telesne mase in delež
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
mladostnikov, pri katerih se je telesna masa klinič znač poveč sta bila pri dolgotrajni
The frequency terms listed are defined as follows:
izpostavljenosti (najmanj 24 tednov) več kot pri kratkotrajni. ja
Very common (≥ 10%), common (≥ 1% and < 10%).
pogosti (≥10%) in pogosti (≥1% in < 10%).
Metabolism and nutrition disorders Very common:
Pogostost než elenih uč inkov
Weight gain9, elevated triglyceride levels10, increased appetite.
Presnovne in prehranske motnje zelo pogosti: poveč telesne mase9, zviš ravni trigliceridov10, poveč apetit pogosti: zviš ravni ane Bolezni ž evja ivč
11 Common:
anje holesterola 11
Sedation (including: hypersomnia, lethargy, somnolence).
zelo pogosti: sedacija (vključ s hipersomnijo, letargijo, zaspanostjo) no Bolezni prebavil pogosti: suha usta Bolezni jeter, ž nika in ž evodov
Gastrointestinal disorders Common:
olč
Elevations of hepatic transaminases (ALT/ AST; see section 4.4).
zelo pogosti: zviš ravni jetrnih transaminaz (ALT/ AST; gl. poglavje 4. 4) ane Preiskave zelo pogosti: nizke ravni skupnega bilirubina, visoka raven GGT (gama- glutamil transferaze), poveč plazemske koncentracije prolaktina12 ane
Decreased total bilirubin, increased GGT, elevated plasma prolactin levels12.
Poveč telesne mase (kg) glede na izhodišno je bilo zelo pogosto (za ≥7%) in pogosto (za č 9 anje ≥15%).
9 Weight gain ≥ 7% of baseline body weight (kg) was very common and ≥ 15% of baseline body weight was common.
Pri dolgotrajni izpostavljenosti (najmanj 24 tednov) je približ polovica mladostnikov no pridobila ≥15% in skoraj tretjina ≥25% od izhodišne telesne mase.
With long-term exposure (at least 24 weeks), approximately half of adolescent patients gained ≥ 15% and almost a third gained ≥ 25% of their baseline body weight.
Med mladostniki je bilo č povpreč poveč več pri bolnikih, ki so bili v osnovi predebeli ali debeli.
Among adolescent patients, mean weight gain was greatest in patients who were overweight or obese at baseline.
Opazovano pri normalnih osnovnih vrednostih na teše (< 1, 016 mmol/ l), ki so se zviš na visoke ale č (≥1, 467 mmol/ l).
10 Observed for fasting normal levels at baseline (< 1.016 mmol/ l) which increased to high (≥ 1.467 mmol/ l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/ l - < 1.467 mmol/ l) to high (≥ 1.467 mmol/ l).
Vrednosti trigliceridov na teše so se z mejnih osnovnih vrednosti (≥1, 016 mmol/ l do < 1, 467 mmol/ l) spremenile na visoke (≥1, 467 mmol/ l).
11 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/ l) to high (≥ 5.17 mmol/ l) were observed commonly.
č 11 Pogosto so opazovali spremembe vrednosti skupnega holesterola na teše, ki so se z normalnih osnovnih vrednosti (< 4, 39 mmol/ l) zviš na visoke (≥
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - < 5.17 mmol/ l) to high (≥ 5.17 mmol/ l) were very common.
spremembe vrednosti skupnega holesterola na teše z mejnih osnovnih vrednosti (≥4, 39 mmol/ l do < 5, 17 mmol/ l) na visoke (≥5, 17 mmol/ l).
12 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
12 O poveč plazemskih koncentracijah prolaktina so poroč pri 47, 4% mladostnikov.
Signs and symptoms Very common symptoms in overdose (> 10% incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Znaki in simptomi Zelo pogosti simptomi pri prevelikem odmerjanju (incidenca > 10%) vključ ujejo tahikardijo, vznemirjenost/ nasilnost, dizartrijo, različ ekstrapiramidne simptome in motnje zavesti v razponu od ne sedacije do kome.
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (< 2% of overdose cases) and cardiopulmonary arrest.
Poroč
Fatal outcomes have been reported for acute overdoses as low as 450 mg but survival has also been reported following acute overdose of 1,500 mg.
so o smrtnih izidih po akutnih prevelikih odmerjanjih tako majhnih odmerkov, kot je 450 mg, vendar so poroč tudi o prež
10 Management of overdose There is no specific antidote for olanzapine.
ivetju po akutnem prevelikem odmerjanju z odmerkom 1500 mg.
Induction of emesis is not recommended.
Sprož bruhanja ni priporoč Lahko so indicirani
Standard procedures for management of overdose may be indicated (i. e. gastric lavage, administration of activated charcoal).
standardni postopki za zdravljenje prevelikega odmerka (tj. izpiranje želodca, dajanje aktivnega oglja).
The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60%.
Izkazalo se je, da se ob sočasnem jemanju aktivnega oglja peroralna biološ uporabnost olanzapina ka zmanjš za 50 do 60%. a
Symptomatic treatment and monitoring of vital organ function should be instituted according to clinical presentation, including treatment of hypotension and circulatory collapse and support of respiratory function.
Glede na klinič sliko je treba uvesti simptomatsko zdravljenje hipotenzije in cirkulatorne odpovedi no ter podpreti dihanje in spremljati delovanje vitalnih organov.
Do not use epinephrine, dopamine, or other sympathomimetic agents with beta- agonist activity since beta stimulation may worsen hypotension.
Ne uporabljajte adrenalina, dopamina ali drugih simpatikomimetikov z betaagonistič delovanjem, ker lahko beta stimulacija poslabš
Cardiovascular monitoring is necessary to detect possible arrhythmias.
S skrbnim
Close medical supervision and monitoring should continue until the patient recovers.
zdravstvenim nadzorovanjem in opazovanjem je treba nadaljevati, dokler si bolnik ne opomore.
Pharmacotherapeutic group: antipsychotics: diazepines, oxazepines and thiazepines, ATC code:
Farmakoterapevtska skupina: diazepini, oksazepini in tiazepini, oznaka ATC:
Olanzapine is an antipsychotic, antimanic and mood stabilising agent that demonstrates a broad pharmacologic profile across a number of receptor systems.
enja, ki kaž š farmakološ profil prek Olanzapin je antipsihotik, antimanik in stabilizator razpoliž številnih receptorskih sistemov.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nM) for serotonin 5 HT2A/ 2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors m1-m5; α adrenergic; and histamine H1 receptors.
V predklinič raziskavah z olanzapinom se je pokazal razpon afinitete do receptorjev nih (Ki; < 100 nM) za serotonin (5- HT2A/ 2C, 5- HT 3, 5- HT 6) in dopamin (D1, D2, D3, D4, D5), do holinergič muskarinskih receptorjev (m1– m5), adrenergič receptorjev α in histaminskih
Animal behavioral studies with 1 olanzapine indicated 5HT, dopamine, and cholinergic antagonism, consistent with the receptor- binding profile.
Vedenjske raziskave na živalih so kazale na 5- HT, dopaminski in holinergič antagonizem v skladu s profilom vezave na receptorje.
Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5 HT2 than D2 activity in vivo, models.
afiniteto za serotoninske 5- HT2 kot za dopaminske receptorje D2, v modelih in vivo pa več aktivnost jo 5- HT 2 kot D2.
Electrophysiological studies demonstrated that olanzapine selectively reduced the firing of mesolimbic (A10) dopaminergic neurons, while having little effect on the striatal (A9) pathways involved in motor function.
Elektrofiziološ raziskave so pokazale, da je olanzapin selektivno zmanjš prož mezolimbič (A10) dopaminergič nih
Olanzapine reduced a conditioned avoidance response, a test indicative of antipsychotic activity, at doses below those producing catalepsy, an effect indicative of motor side-effects.
ki pokaž antipsihotič delovanje pri manjš odmerkih od tistih, ki povzroč katalepsijo, tj. uč
Unlike some other antipsychotic agents, olanzapine increases responding in an “ anxiolytic” test.
Za razliko od nekaterih drugih antipsihotikov olanzapin poveč
In a single oral dose (10 mg) Positron Emission tomography (PET) study in healthy volunteers, olanzapine produced a higher 5 HT2A than dopamine D2 receptor occupancy.
Pri pozitronski emisijski tomografiji (PET) s posameznim peroralnim odmerkom (10 mg) pri zdravih prostovoljcih je olanzapin povzroč več zasedenost receptorjev 5- HT 2A kot dopaminskih receptorjev
In addition, a SPECT imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Slikovna raziskava SPECT (Single Photon Emission Computed Tomography) je pri bolnikih s shizofrenijo razkrila, da je bila zasedenost striatnih receptorjev D 2 pri bolnikih, ki so se odzivali na olanzapin, manjš kot pri bolnikih, ki so se odzivali na nekatere druge antipsihotike in na risperidon, a medtem ko je bila primerljiva z bolniki, ki so se odzivali na klozapin.
In two of two placebo and two of three comparator controlled trials with over 2,900 schizophrenic patients presenting with both positive and negative symptoms, olanzapine was associated with statistically significantly greater improvements in negative as well as positive symptoms.
Pri dveh od dveh s placebom kontroliranih in dveh od treh primerjalno kontroliranih preizkuš anjih na več 2900 bolnikih s shizofrenijo, ki so imeli tako pozitivne kot negativne simptome, je olanzapin kot statistič znač izboljš negativne in tudi pozitivne simptome.
In a multinationational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p=0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).
V dvojno slepi primerjalni raziskavi shizofrenije ter shizoafektivnih in sorodnih motenj, v kateri je sodelovalo več av in skupaj 1481 bolnikov z različ
In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks.
uč inkovito zmanjš jakost manič simptomov kot placebo in seminatrijev valproat (divalproeks).
In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition
V raziskavi, v kateri so vsaj dva tedna spremljali soč asno zdravljenje bolnikov z litijem ali valproatom, je dodatek 10 mg olanzapina bolj zmanjš jakost simptomov manije po 6 tednih kot pri monoterapiji z litijem ali al valproatom.